These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 15330686)

  • 1. Future antidepressants: what is in the pipeline and what is missing?
    Bosker FJ; Westerink BH; Cremers TI; Gerrits M; van der Hart MG; Kuipers SD; van der Pompe G; ter Horst GJ; den Boer JA; Korf J
    CNS Drugs; 2004; 18(11):705-32. PubMed ID: 15330686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
    Adell A
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current trends in the development of new antidepressants.
    Pacher P; Kohegyi E; Kecskemeti V; Furst S
    Curr Med Chem; 2001 Feb; 8(2):89-100. PubMed ID: 11172668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.
    Millan MJ
    Neurotherapeutics; 2009 Jan; 6(1):53-77. PubMed ID: 19110199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoaminergic system and depression.
    Perez-Caballero L; Torres-Sanchez S; Romero-López-Alberca C; González-Saiz F; Mico JA; Berrocoso E
    Cell Tissue Res; 2019 Jul; 377(1):107-113. PubMed ID: 30627806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited review: the evolution of antidepressant mechanisms.
    Slattery DA; Hudson AL; Nutt DJ
    Fundam Clin Pharmacol; 2004 Feb; 18(1):1-21. PubMed ID: 14748749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
    Bymaster FP; McNamara RK; Tran PV
    Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides.
    Catena-Dell'Osso M; Fagiolini A; Marazziti D; Baroni S; Bellantuono C
    Mini Rev Med Chem; 2013 Jan; 13(1):2-10. PubMed ID: 22876945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies for pharmacotherapy of depression.
    Maubach KA; Rupniak NM; Kramer MS; Hill RG
    Curr Opin Chem Biol; 1999 Aug; 3(4):481-8. PubMed ID: 10419849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some current problems related to the mode of action of antidepressant drugs.
    Carlsson A
    Acta Psychiatr Scand Suppl; 1981; 290():63-6. PubMed ID: 6939325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
    Prins J; Olivier B; Korte SM
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to antidepressant drug discovery: beyond monoamines.
    Berton O; Nestler EJ
    Nat Rev Neurosci; 2006 Feb; 7(2):137-51. PubMed ID: 16429123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe depression: is there a best approach?
    Sonawalla SB; Fava M
    CNS Drugs; 2001; 15(10):765-76. PubMed ID: 11602003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the horizons of depression: beyond the monoamine hypothesis.
    Hindmarch I
    Hum Psychopharmacol; 2001 Apr; 16(3):203-218. PubMed ID: 12404573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.